[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].

Purpose: To evaluate the results of preoperative chemoradiation for resectable bulky cervical carcinoma without lymph node involvement after surgical lymph node staging.

Patients And Methods: Between 2000 and 2010, 45 patients with cervical carcinoma stage IB2 (11 patients), IIA2 (3 patients) and IIB with proximal parametrial invasion (31 patients) were treated with pelvic radiation therapy at a dose of 40.5Gy and concurrent platin (44 patients) or mitomycin (one patient).

[Ductal carcinoma in situ treated with radiation therapy and additional boost].

Purpose: Women with ductal carcinoma in situ are treated with breast-conserving surgery and radiation therapy. The impact of an additive boost radiation is under evaluation.

Patients And Methods: All women treated for ductal carcinoma in situ with breast-conserving surgery and whole breast radiation therapy at a total dose of 45Gy with a boost radiation from 1990 to 2008 have been included in this retrospective monocentric retrospective study.

[Influence of body mass index on the outcomes of robotic-assisted laparoscopic sacrocolpopexy: a comparative retrospective study].

Objective: The aim of our study was to assess the impact of body mass index (BMI) on a robot-assisted laparoscopic sacrocolpopexy (RALS) to treat genital prolapse.

Methodology: The study focused on a group of 56 women who went through a robot-assisted laparoscopic sacrocolpopexy (RALS) between 2009 and 2013. Patients were divided into 3 groups according to their BMI (kg/m(2)): BMI<25 (n=28), 25≤BMI<30 (n=16), BMI≥30 (n=12).

[Preliminary study on the feasibility of robot-assisted double mesh sacrocolpopexy in comparison to the laparoscopic approach].

Objectives: The aim of our study was to demonstrate the feasibility of the laparoscopic robot-assisted anterior and posterior mesh sacrocolpopexy compared to the laparoscopic approach.

Materials And Methods: Between November 2009 and August 2011, 36 women underwent sacrocolpopexy with anterior and posterior mesh, 16 by a robot-assisted approach and 20 by laparoscopy. The cases were systematically evaluated at 1 and 12 months postoperatively.

[Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].

Ovarian carcinoma is account for 4% of all women cancer deaths because of late diagnosis at advanced stage. During chemotherapy, survey includes repeated assays of antigen carbohydrate 125 (CA125), which is a membrane glycoprotein belonging to the mucin family and secreted by 80% of the serous ovarian tumours. The aim of this study was to analyze the clinical relevance of a follow-up of CA125 kinetics of five ovarian carcinoma patients at advanced stages and under neoadjuvant chemotherapy.